<div id="readability-page-1"><p>Greenup Street Wealth Management LLC purchased a new stake in shares of  Medtronic PLC (NYSE:MDT - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  purchased 13,709 shares of the medical technology company's stock, valued at approximately $1,306,000.</p><ul><li>Medtronic Stock Finds Its Footing—Now It’s Gaining Momentum</li></ul><p>Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of  Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock valued at $3,194,000 after buying an additional 37,265 shares in the last quarter.  CreativeOne Wealth LLC raised its position in  Medtronic by 13.1% during the first quarter. CreativeOne Wealth LLC now owns 14,110 shares of the medical technology company's stock worth $1,268,000 after acquiring an additional 1,631 shares in the last quarter.  Trexquant Investment LP acquired a new stake in  Medtronic in the first quarter valued at $3,006,000.  WPG Advisers LLC acquired a new stake in  Medtronic in the first quarter valued at $96,000.  Finally, GKV Capital Management Co. Inc. bought a new position in shares of  Medtronic in the 1st quarter valued at about $178,000. 82.06% of the stock is currently owned by institutional investors. </p><h2>Medtronic Trading Down 0.8%</h2><p>Shares of MDT stock opened at $96.52 on Friday. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $106.33. The company has a market capitalization of $123.74 billion, a PE ratio of 26.02, a price-to-earnings-growth ratio of 2.56 and a beta of 0.71. The firm has a 50 day moving average price of $97.54 and a two-hundred day moving average price of $93.72. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. </p><ul><li>MarketBeat Week in Review – 08/18 - 08/22</li></ul><p>Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm's revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS.  As a group, analysts predict that  Medtronic PLC will post 5.46 earnings per share for the current year. </p><h2>Medtronic Announces Dividend</h2><p>The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be given a dividend of $0.71 per share. The ex-dividend date is Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic's dividend payout ratio (DPR) is presently 76.55%. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Medtronic: The Opportunity Gets Healthier for Income Investors</li></ul><p>A number of brokerages have recently issued reports on MDT. Daiwa Capital Markets upped their target price on shares of Medtronic from $104.00 to $117.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, November 25th. Robert W. Baird  set a $103.00 price target on Medtronic in a research report on Tuesday, December 16th. Citigroup raised their price objective on Medtronic from $101.00 to $112.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, October 7th. Weiss Ratings  reiterated a &#34;buy (b)&#34; rating on shares of Medtronic in a research note on Monday, December 15th. Finally, Morgan Stanley boosted their target price on Medtronic from $107.00 to $117.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, November 19th. One research analyst  has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $109.94.</p><p><b>View Our Latest Stock Analysis on Medtronic</b></p><h2>Medtronic Profile</h2> (Free Report)<p>Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.  </p><p>Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Medtronic</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Do you know what Amazon is planning for January 1?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><strong>Want to see what other hedge funds are holding MDT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Medtronic Right Now?</h2><p>Before you consider Medtronic, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.</p><p>While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Greenup Street Wealth Management LLC has acquired 13,709 shares of Medtronic PLC, valued at approximately $1,306,000, as per their latest SEC filing. Medtronic, a global medical technology company, has seen various institutional investors adjusting their stakes. The company's stock is currently trading at $96.52, with a market cap of $123.74 billion. Medtronic recently reported quarterly earnings of $1.36 per share, surpassing estimates, and announced a quarterly dividend of $0.71 per share. Analysts have given the stock a "Moderate Buy" rating with a target price of $109.94.</p>

Greenup Street Wealth Management LLC Buys New Shares in Medtronic PLC $MDT